• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Falls; GreenPower Motor Company Shares Spike Higher

    7/17/23 3:05:29 PM ET
    $BBIO
    $GNTY
    $GP
    $JZXN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Banks
    Finance
    Get the next $BBIO alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 0.25% on Monday.

    The Dow traded up 0.25% to 34,596.04 while the NASDAQ rose 0.92% to 14,243.64. The S&P 500, also rose, gaining, 0.43% to 4,524.74.

    Check This Out: Baidu To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Monday

     

    Leading and Lagging Sectors

    • Financial shares climbed by 1.1% on Monday.
    • In trading on Monday, utilities shares fell by 0.7%.

     

    Top Headline

    Guaranty Bancshares, Inc. (NYSE:GNTY) reported better-than-expected second-quarter financial results.

    Guaranty Bancshares posted quarterly earnings of 81 cents per share, topping market estimates of 56 cents per share. The company’s quarterly sales came in at $32.58 million, versus expectations of $29.48 million.

     

    Equities Trading UP

    • ProMIS Neurosciences, Inc. (NASDAQ:PMN) shares shot up 109% to $5.86. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived antibody and vaccine from Alzheimer's pipeline.
    • Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) got a boost, shooting 80% to $32.74 after the company's Phase 3 ATTRibute-CM study of acoramidis for transthyretin amyloid cardiomyopathy met its primary endpoint.
    • GreenPower Motor Company Inc. (NASDAQ:GP) shares were also up, gaining 43% to $4.9750 after the company reported better-than-expected fourth-quarter sales results.

     

    Equities Trading DOWN

    • Novan, Inc. (NASDAQ:NOVN) shares dropped 71% to $0.1798 after the company entered into agreement to sell substantially all of its assets, including Berdazimer Gel, 10.3%, and filed for Chapter 11 protection.
    • Shares of ViewRay, Inc. (NASDAQ:VRAY) were down 79% to $0.0777 after the company filed voluntary Chapter 11 petitions.
    • Jiuzi Holdings, Inc. (NASDAQ:JZXN) was down, falling 55% to $1.50 after the company announced pricing of a $2.3 million registered direct offering.

    Also Check This Out: General Motors, Alphabet And 2 Other Stocks Insiders Are Selling

     

    Commodities

    In commodity news, oil traded down 1.8% to $74.08 while gold traded down 0.3% at $1,957.90.

    Silver traded down 0.6% to $25.035 on Monday while copper fell 2.2% to $3.8450.

     

    Euro zone

    European shares closed mostly lower today. The eurozone’s STOXX 600 fell 0.63%, London’s FTSE 100 slipped 0.38% while Spain’s IBEX 35 Index slipped 0.01% The German DAX declined 0.23% French CAC 40 declined 1.12% and Italy’s FTSE MIB Index fell 0.19%.

    The annual inflation rate in Italy eased to a 14-month low level of 6.4% in June, down from 7.6% in the earlier month.

     

    Asia Pacific Markets

    Asian markets closed mixed on Monday, with China’s Shanghai Composite Index falling 0.87% and India’s S&P BSE Sensex rising 0.8%.

    The Chinese economy advanced by 6.3% year-over-year during the second quarter, higher than a 4.5% growth in the prior quarter, but missing expectations of 7.3%. Chinese retail sales rose by 3.1% year-over-year in June, compared to a 12.7% growth in May. The country’s industrial production climbed 4.4% year-over-year in June, topping market views of 2.7%, while average new home prices in the country came in flat year-over-year in June. The People's Bank of China held its one-year medium-term lending facility rate at 2.65%.

     

    Economics

    The NY Empire State Manufacturing Index fell by 5.5 points from the prior month to a reading of +1.1 in July, topping market estimates of -4.3.

    Now Read This: Top 5 Financial Stocks That Could Blast Off In July

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 107,394,980 cases with around 1,168,880 deaths. India confirmed a total of at least 44,994,870 cases and 531,910 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 691,481,970 cases of COVID-19 worldwide with more than 6,899,730 deaths.

    Get the next $BBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBIO
    $GNTY
    $GP
    $JZXN

    CompanyDatePrice TargetRatingAnalyst
    BridgeBio Pharma Inc.
    $BBIO
    3/10/2026Outperform
    William Blair
    BridgeBio Pharma Inc.
    $BBIO
    1/28/2026$157.00Overweight
    Barclays
    BridgeBio Pharma Inc.
    $BBIO
    1/6/2026$96.00Overweight
    Morgan Stanley
    BridgeBio Pharma Inc.
    $BBIO
    12/11/2025$94.00Outperform
    Bernstein
    BridgeBio Pharma Inc.
    $BBIO
    7/30/2025$56.00Outperform
    Raymond James
    BridgeBio Pharma Inc.
    $BBIO
    7/21/2025$66.00Buy
    Truist
    BridgeBio Pharma Inc.
    $BBIO
    7/14/2025$70.00Buy
    Jefferies
    BridgeBio Pharma Inc.
    $BBIO
    7/9/2025$60.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $BBIO
    $GNTY
    $GP
    $JZXN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by BridgeBio Pharma Inc.

    SCHEDULE 13G/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    3/26/26 4:41:34 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by ProMIS Neurosciences Inc.

    S-3 - ProMIS Neurosciences Inc. (0001374339) (Filer)

    3/25/26 5:22:52 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by ProMIS Neurosciences Inc.

    10-K - ProMIS Neurosciences Inc. (0001374339) (Filer)

    3/25/26 4:34:05 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    $GNTY
    $GP
    $JZXN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on BridgeBio Pharma

    William Blair initiated coverage of BridgeBio Pharma with a rating of Outperform

    3/10/26 8:40:05 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on BridgeBio Pharma with a new price target

    Barclays initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $157.00

    1/28/26 7:16:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on BridgeBio Pharma with a new price target

    Morgan Stanley initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $96.00

    1/6/26 8:54:42 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    $GNTY
    $GP
    $JZXN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

    PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adverse events reported to date Cambridge, Massachusetts,, March 25, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinso

    3/25/26 8:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

    PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that long-term efficacy and safety data in patients with ATTR-CM from the open-label extension (OLE) trial of ATTRibute-CM, its Phase 3 study of acoramidis, will be shared in a late-breaking oral presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in New Orleans, Louisiana on March 28-30, 2026. Additionally, BridgeBio was selected to share three posters on additional OLE data and real-world survey findings. Late-Break

    3/23/26 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JZXN to Deliver 100 Electric Heavy-Duty Trucks to Vietnam Market

    HANGZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- Jiuzi Holdings, Inc. (NASDAQ:JZXN, the "Company" or "Jiuzi")), today announced that the Company has recently completed a series of important business negotiations in Vietnam and has reached cooperation intentions with multiple local customers. The Company expects to deliver an initial batch of over 100 electric heavy-duty trucks to the Vietnam market. This milestone marks that Jiuzi's strategic positioning in the Southeast Asian new energy commercial vehicle market has entered a substantive implementation phase. Vietnam Market: A Strategic Hub for Southeast Asian Electric Commercial Vehicles As one of the fastest-growing economies in S

    3/23/26 7:15:00 AM ET
    $JZXN
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $BBIO
    $GNTY
    $GP
    $JZXN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    $GNTY
    $GP
    $JZXN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Trimarchi Thomas

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    3/20/26 4:33:58 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Apuli Maricel

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    3/20/26 4:32:18 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kumar Neil

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    3/19/26 4:28:10 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    $GNTY
    $GP
    $JZXN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Eugene bought $48,800 worth of shares (2,000 units at $24.40), increasing direct ownership by 19% to 12,397 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    3/6/26 7:28:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Williams Eugene bought $92,420 worth of shares (4,000 units at $23.11), increasing direct ownership by 63% to 10,397 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    3/4/26 6:08:32 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Kaplan Johanne bought $25,005 worth of shares (1,629 units at $15.35), increasing direct ownership by 70% to 3,941 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    2/23/26 8:31:05 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    $GNTY
    $GP
    $JZXN
    Leadership Updates

    Live Leadership Updates

    View All

    New Jersey ZIP Reopens with $37.5 Million in New Funding

    GreenPower's EV Star Line-up Eligible for more than $90,000 in Incentives HAINESPORT, N.J., Nov. 24, 2025 /PRNewswire/ -- GreenPower Motor Company Inc. (NASDAQ:GP) ("GreenPower"), a leading manufacturer and distributor of all-electric, purpose-built, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, today announced that its EV Star line of products are eligible for incentives under the reopened New Jersey Zero-Emission Incentive Program (NJ ZIP). GreenPower has a full lineup of Class 4 commercia

    11/24/25 8:30:00 AM ET
    $GP
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

    Appointment reinforces ProMIS Neurosciences' strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer's program, PMN310 Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Slanix Paul Alex, Pharm.D., President and Portfolio Manager for Ally Bridge Group's Public Equity strategy, has joined the Company's Board of Directors. Dr. Alex has a highly distinguished Wall Street career spanning multiple leadership positions at public market

    10/22/25 7:30:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Following the Appointment of Dr. Doug Buerger as COO, Jiuzi Holdings, Inc.'s Board Endorses Crypto Asset Investment Policy Allowing Up to $1 Billion Deployment

    HANGZHOU, China, Sept. 24, 2025 /PRNewswire/ -- Jiuzi Holdings, Inc. (NASDAQ:JZXN, the ", Company", )) today announced that its Board of Directors has formally approved and adopted a Crypto Asset Investment Policy (hereinafter referred to as the "Policy"). This policy authorizes the Company to allocate portions of its cash reserves into select crypto assets within a prudent risk management framework. This strategic initiative follows the recent appointment of industry-renowned crypto expert Dr. Doug Buerger as Chief Operating Officer (COO), after thorough research and careful evaluation. CEO Tao Li stated, "Adopting the Crypto Asset Investment Policy represents a proactive step in our treas

    9/24/25 7:15:00 AM ET
    $JZXN
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $BBIO
    $GNTY
    $GP
    $JZXN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

    SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 4:56:13 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ProMIS Neurosciences Inc.

    SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 3:36:04 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

    SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    11/6/24 5:04:05 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    $GNTY
    $GP
    $JZXN
    Financials

    Live finance-specific insights

    View All

    ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

    PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adverse events reported to date Cambridge, Massachusetts,, March 25, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinso

    3/25/26 8:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

    $154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration of its unique model for sustainable drug development as described in a recent peer-reviewed manuscriptAttruby continues to demonstrate clinical differentiation as a first-choice therapy in ATTR-CM with the greatest TTR stabilization on the market (≥90%) and the most rapid benefit on clinical outcomes observed within 1 month, with 7,804 unique patient prescriptions written by 1,856 unique prescribers as

    2/24/26 4:01:00 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

    PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentat

    2/17/26 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care